(Single Scrip Lending) List of Approved Securities
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Terms and Conditions for the Icici Bank Indian Rupee Travel Card
TERMS AND CONDITIONS FOR THE ICICI BANK INDIAN RUPEE TRAVEL CARD The following terms and conditions (“Terms and Conditions”) apply to the ICICI Bank Travel Card facility provided by ICICI Bank. For your own benefit and protection you should read these terms and conditions carefully before availing ICICI Bank Indian Rupee Travel Card. These are ICICI Bank’s standard terms and conditions on the basis of which it provides the ICICI Bank Indian Rupee Travel Card. If you do not understand any of the terms or conditions, please contact us for further information. Your use of the ICICI Bank Indian Rupee Travel Card will indicate your acceptance of these terms and conditions. ICICI Bank Indian Rupee Travel Card is issued by ICICI Bank and distributed by ICICI Bank UK PLC to the customers in the United Kingdom (UK). ICICI Bank Limited is incorporated in India and regulated by the Reserve Bank of India (RBI). ICICI Bank UK PLC is a 100% owned subsidiary of ICICI Bank Limited. ICICI Bank UK PLC’s role is solely to distribute the INR Travel Cards to individuals in the UK and assist in facilitating the documentation to initiate the relationship with ICICI Bank. Definitions In these Terms and Conditions, the following words have the meanings set out hereunder, unless the context indicates otherwise. “ICICI Bank Limited”, means ICICI Bank Limited, a company incorporated under the Companies Act. 1956 of India and licensed as a bank under the Banking Regulation Act, 1949 and having its registered office at Landmark, Race Course Circle, Vadodara 390 007, and its corporate office at ICICI Bank Towers, Bandra Kurla Complex, Mumbai 400 051. -
Indiaghg-Aug15 0.Pdf
The India Greenhouse Gas (GHG) Program is a voluntary, industry-led partnership, focused on building institutional capabilities towards measuring and managing greenhouse gas emissions, based on the GHG Protocol WHO WE ARE The India GHG Program was launched in July 2013 by WRI India, The Energy and Resources Institute (TERI), and the Confederation of Indian Industry (CII), with support from India’s key businesses as founding member companies. Several progressive companies, including automotive, aviation, telecom, cement, chemicals, manufacturing, financial services, information technology, consumer, agri-business, textiles, and others are voluntary members of the Program. The total inventory managed by businesses under the India GHG Program ranges from 300 to 360 million TCO2e. This is equivalent to 15 to 25 percent of India’s total emissions. What climate change challenges does India face? While it is difficult to quantify the expected impact of climate change, a recent orldW Bank study indicates that countries like India will need USD 70 to 100 billion each year through 2050 to meet the current and future climate adaptation needs. However, our current spending is around USD 4.4 billion. The challenges, including water availability, changing rainfall patterns, resilience capabilities, disaster management, and others hold serious implications for communities, businesses, and for the country’s future growth and development. What role can the corporate sector play? Businesses are not only essential for continued economic growth, but they also have an immense opportunity in aiding large-scale reduction of emissions which can help mitigate the impacts of climate change. Approximately 38 percent of India’s greenhouse gas emissions come from energy generation and industrial and commercial users consume about 76 percent of that energy. -
List of Nodal Officers
List of Nodal Officers S. Name of Bank Name of the Nodal Address CPPC Phone/Fax No./e-mail No Officers 1 Allahabad Bank Dr S R Jatav Asstt. General Manager, Office no: 0522 2286378, 0522 Allahabad Bank, CPPC 2286489 Zonal Office Building, Mob: 08004500516 Ist floor,Hazratganj, [email protected] Lucknow UP-226001 2 Andhra Bank Shri M K Srinivas Sr.Manager, Mob: 09666149852,040-24757153 Andhra Bank, [email protected] Centralized Pension Processing Centre(CPPC) 4th floor,Andhra Bank Building,Koti, Hyderabad-500095 3 Axis Bank Shri Hetal Pardiwala, Nodal Officer Mob: 9167550333, AXIS BANK LTD, Gigaplex Bldg [email protected] no.1, 4th floor, Plot No. I.T.5, MIDC, Airoli Knowledge Park, Airoli, Navi Mumbai- 400708 4 Bank of India Shri R. Ashok Chief Manager 0712-2764341, Ph.2764091,92 Nimrani Bank of India, 0712-2764091 (fax) CPPC Branch, Bank of India Bldg. [email protected] 87-A, 1st floor, Gandhibaug, Nagpur-440002. 5 Bank of Baroda Shri S K Goyal, Dy. General Manager, 011-23441347, 011-23441342 Bank of Baroda, [email protected] Central Pension Processing Centre, [email protected] Bank of Baorda Bldg. 16, Parliament Street, New Delhi – 110 001 6 Bank of Shri D H Vardy Manager Ph: 020-24467937/38 Maharashtra Bank of Maharashtra Mob: 08552033043 Central Pension Processing Cell, [email protected] 1177, Budhwar Peth, Janmangal, Bajirao Road Pune-411002 7 Canara Bank Shri K S Hebbar Asstt. General Manager Mob. 08197844215 Canara Bank Ph: 080 26621845 Centralized Pension Processing [email protected] Centre Dwarakanath Bhavan 29, K R Road Basavangudi, Bangalore 560 004 8 Central Bank of Shri V K Sinha Chief Manager Ph: 022-22703216/22703217, India Central Bank of India (CPPC) Fax- 22703218 Central Office, 2nd Floor, [email protected] Central Bank Building, M.G. -
Big Power Trade - Futuros National Stock Exchange of India (NSE)
BiG Power Trade - Futuros National Stock Exchange of India (NSE) País / Região Bolsa Produto Horário Futuros (Moeda, National Stock Exchange of India (NSE) Segunda-feira - Sexta-feira: Acções, Índices de 9:15-15:30 IST* Índia www.nseindia.com acções) IB Simbolo Instrumento Simbolo Moeda ACC ACC LIMITED ACC INR ADANIPOWE ADANI POWER LIMITED ADANIPOWER INR AJANTPHAR AJANTA PHARMA LTD AJANTPHARM INR ALBK ALLAHABAD BANK ALBK INR AMARAJABA AMARA RAJA BATTERIES LTD AMARAJABAT INR AMBUJACEM AMBUJA CEMENTS LIMITED AMBUJACEM INR ANDHRABAN ANDHRA BANK ANDHRABANK INR APOLLOHOS APOLLO HOSPITALS ENTERPRISE APOLLOHOSP INR APOLLOTYR APOLLO TYRES LIMITED APOLLOTYRE INR ARVIND ARVIND LTD ARVIND INR ASHOKLEY ASHOK LEYLAND LIMITED ASHOKLEY INR ASIANPAIN ASIAN PAINTS LTD ASIANPAINT INR AUROPHARM AUROBINDO PHARMA LTD AUROPHARMA INR AXISBANK AXIS BANK LTD AXISBANK INR BAJAJ-AUT BAJAJ AUTO LIMITED BAJAJ-AUTO INR BAJAJFINS BAJAJ FINSERV LTD BAJAJFINSV INR BAJFINANC BAJAJ FINANCE LTD BAJFINANCE INR BALKRISIN BALKRISHNA INDUSTRIES LTD BALKRISIND INR BALRAMCHI BALRAMPUR CHINI MILLS LTD BALRAMCHIN INR BANKBAROD BANK OF BARODA BANKBARODA INR BANKINDIA BANK OF INDIA BANKINDIA INR BANKNIFTY Nifty Bank BANKNIFTY INR BATAINDIA BATA INDIA LTD BATAINDIA INR BEL BHARAT ELECTRONICS LTD BEL INR BEML BEML LIMITED BEML INR BERGEPAIN BERGER PAINTS INDIA LTD BERGEPAINT INR BHARATFIN BHARAT FINANCIAL INCLUSION L BHARATFIN INR BHARATFOR BHARAT FORGE LIMITED BHARATFORG INR BHARTIART BHARTI AIRTEL LIMITED BHARTIARTL INR BHEL BHARAT HEAVY ELECTRICALS BHEL INR BIOCON BIOCON LTD BIOCON -
SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI Trading As ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP
Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI trading as ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP. COTTON GREEN RLY. STN. MUMBAI-400033. MANUFACTURE & MERCHANT INDIAN NATIONAL Used Since :31/01/2001 MUMBAI MEDICINAL PREPARATIONS. 537 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SEPTIGARD 1741718 08/10/2008 INDERJIT SINGH trading as ;INDERJIT SINGH B-104 , SWASTHYA SINGH , NEW DELHI -92 MERCHANTS & MANUFACTUERERS Address for service in India/Agents address: MAHTTA & CO. 43 - B/3, MAHTTA HOUSE,UDHAM SINGH NAGAR, LUDHIANA - 141 001, (PUNJAB). Proposed to be Used DELHI MEDICINAL & PHARMACEUTICAL PREPARATIONS. 538 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 FAIR & BEAUTY 1803779 08/04/2009 GALPHA LABORATORIES LIMITED 221, Kanakia Zillion, E Wing Bandra Kurla Complex Annex LBS Marg & CST Road Junction Kurla West MUMBAI 400070 MANUFACTURERS AND MERCHANTS INDIAN NATIONAL Used Since :15/11/2007 MUMBAI PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES 539 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 O-BAMA 1815900 08/05/2009 KREMOINT PHARMA PVT. LTD. 151/5, SHRI KRISHNA DARSHAN, GARODIA NAGAR, GHATKOPAR (E), BOMBAY-400 077. MANUFACTURERS AND MERCHANTS. A CORPORATE ENTITY INCORPORATED IN INDIA UNDER THE COMPANIES ACT 1956. Address for service in India/Attorney address: KRISLAW CONSULTANTS BUILDING NO.4, C/104, SHANKESHWAR PALMS, BEHIND MODEL SCHOOL, KUMBHARKHANPADA, SUBHASH ROAD, DOMBIVILI(W) 421202 Used Since :02/05/2009 MUMBAI PHARMACETICAL AND MEDICINAL PREPARATIONS. 540 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 AYUSHAKTI D-VYRO 1815928 08/05/2009 SMITA NARAM BUNGALOW NO.31, NEXT TO M. -
Bajaj Hindusthan Sugar Limited
+91-8068442266 Bajaj Hindusthan Sugar Limited https://www.indiamart.com/bajajhindusthansugarlimitedlucknow/ Bajaj Hindusthan Ltd. (BHL), a part of the 'Bajaj Group', is India's Number One sugar and ethanol manufacturing company, headquartered at Mumbai (Maharashtra), India. About Us Bajaj Hindusthan Sugar Limited (BHSL) was incorporated on 23rd November, 1931 under the name - The Hindusthan Sugar Mills Limited – on the initiative of Jamnalal Bajaj - a businessman, confidante, disciple and adopted son of Mahatma Gandhi. He sought Gandhiji's blessings in this new venture, which, apart from being a sound commercial proposition would also meet a national need. Till then, there were barely thirty sugar factories in the country. The site selected for the first plant was at Golagokarannath, district Lakhimpur Kheri in the Terai region of Uttar Pradesh (UP), an area rich in sugar cane. The original capacity of the factory was 400 tons of cane crushed per day (TCD). Subsequently, this capacity was increased in stages and is currently 13,000 TCD. The distillery Unit at this plant commenced production during the end of World War II in 1944. In the initial few years, the major output was in the form of power alcohol as an additive to petrol, which was then in short supply. The unit was the first to supply alcohol-mixed petrol to the army. In 1967, a new Company - Sharda Sugar & Industries Limited - was established as a subsidiary of Hindusthan Sugar Mills Limited. Under this new subsidiary, a sugar plant with a cane crushing capacity of 1400 TCD was set up in 1972 at Palia Kalan, a large cane supplying centre at a distance of about 70 kilometres from Golagokarannath. -
Annual Report 2011-2012
Cover image: All photographs are of associates of Tata Consultancy Services The Annual General Meeting will be held on Friday, June 29, 2012, at Birla Matushri Sabhagar, Sir V. T. Marg, New Marine Lines, Mumbai 400020, at 3.30 p.m. As a measure of economy, copies of the Annual Report will not be distributed at the Annual General Meeting. Members are requested to bring their copies to the meeting. Contents Board of Directors 2 Financial Highlights 4 Our Leadership Team 5 Letter from CEO 6 Key Trends (FY 2005 - 2012) 8 Management Team 10 Directors’ Report 12 Management Discussion and Analysis 21 Corporate Governance Report 58 Consolidated Financial Statements Auditors’ Report 75 Consolidated Balance Sheet 76 Consolidated Statement of Profit and Loss 77 Consolidated Cash Flow Statement 78 Notes forming part of the Consolidated Financial Statements 79 Unconsolidated Financial Statements Auditors’ Report 111 Balance Sheet 114 Statement of Profit and Loss 115 Cash Flow Statement 116 Notes forming part of the Financial Statements 117 Statement under Section 212 of the Companies Act, 1956 relating to subsidiary companies 150 Board of Directors As of April 02, 2012 1 R N Tata 2 S Ramadorai 3 A Mehta Chairman Vice Chairman Director 4 V Thyagarajan 5 C M Christensen 6 R Sommer Director Director Director 7 Laura Cha 8 V Kelkar 9 I Hussain Director Director Director 10 N Chandrasekaran 11 S Mahalingam 12 P A Vandrevala Chief Executive Officer Chief Financial Officer Director and Managing Director and Executive Director 13 O P Bhatt 14 C P Mistry Director -
Everything on BHIM App for UPI-Based Payments
Everything on BHIM app for UPI-based payments BHIM UPI app - From linking bank accounts to sending payments. BHIM is based on UPI, which is the Universal Payments Interface and thus linked directly to a bank account. The new digital payments app calledBHIM is based on the Unified Payments Interface (UPI). The app is currently available only on Android; so iOS, Windows mobile users etc are left out. BHIM is also supposed to support Aadhaar-based payments, where transactions will bepossible just with a fingerprint impression, but that facility is yet to roll out. What can BHIM app do? BHIM is a digital payments solution app based on Unified Payments Interface (UPI) from the National Payments Corporation of India (NPCI). If you have signed up for UPI based payments on your respective bank account, which is also linked to your mobile number, then you’ll be able to use the BHIM app to conduct digital transactions. BHIM app will let you send and receive money to other non-UPI accounts or addresses. You can also send money via IFSC and MMID code to users, who don’t have a UPI-based bank account. Additionally, there’s the option of scanning a QR code and making a direct payment. Users can create their own QR code for a certain fixed amount of money, and then the merchant can scan it and the deduction will be made. BHIM app is like another mobile wallet? No, BHIM app is not a mobile wallet. In case of mobile wallets like Paytm or MobiKwik you store a limited amount of money on the app, that can only be sent to someone who is using the same wallet. -
Financial Village
CONSISTENT COMPOUNDERS AN INVESTMENT STRATEGY BY MARCELLUS INVESTMENT MANAGERS Private & Confidential. 1 ABOUT MARCELLUS Private & Confidential. Marcellus Investment Managers was founded in 2018 and currently has c.US$675m in assets under management and advisory. The founders have worked together for the past 15years Rakshit Ranjan, CFA – Portfolio Saurabh Mukherjea, CFA – Chief Pramod Gubbi, CFA - Head of Sales Investment Officer Manager - Formerly, MD & Head of Institutional - Formerly, Portfolio manager of - former CEO of Ambit Capital, assets Equities at Ambit Capital under advisory were $800mn. Ambit Capital's Coffee Can PMS, - CEO of Ambit Singapore - Author of three bestselling books: which was one of India's top Gurus of Chaos (2014), The Unusual - Tech analyst at Clear Capital and also performing equity products Billionaires (2016) and “Coffee Can worked in the tech industry - HCL during 2018 Investing (2018). Technologies and Philips - Ambit's consumer research - Co-founder of Clear Capital, a London Semiconductors head, voted as No.1 for based small-cap equity research firm which he and his co-founders created in - Post-graduate in Management from Discretionary Consumer and 2003 and sold in 2008. IIM – Ahmedabad. top-3 for Consumer Staples - MSc in Economics from London School - B.Tech from Regional Engineering - At Clear Capital, ranked amongst of Economics College, Surathkal (NIT, Karnataka) the top-3 UK Insurance analysts - Member of SEBI’s Asset Management - B.Tech from IIT (Delhi) 2 Advisory Committee. KEY STEPS FOR IDENTIFYING CONSISTENT COMPOUNDERS 1. Identify companies with clean accounts 2. Identify companies with track record of superior capital allocation 3. Amongst companies which pass steps 1 & 2, identify those with high barriers to entry Private & Confidential. -
Annexure to the Directors' Report
Infosys Annual Report 2011-12 Additional Information Annexure to the Directors' report Information as per Section 217 (2A) of the Companies Act, 1956, read with the Companies (Particulars of employees) Rules 1975, and forming part of the directors’ report for the year ended March 31, 2012 Employee name Title / Role, Unit Qualification Age Experience Joining date Gross Previous employment and (in years) remuneration (`) designation Abhay M. Kulkarni VP and Delivery Head, BE 45 24 Feb 26, 1990 81,23,672 TISCO, Graduate Trainee FSIADM Abhishek VP and Delivery Head, PED B.Tech 39 19 Jul 1, 1993 71,92,874 – Anurag Vardhan Sinha VP and Delivery Head – BE 41 19 Oct 7, 1992 79,74,924 – ADM, Energy, Utilities, Communications and Services, ECSADM Ashok Vemuri Member of the Board and BSC (H), PGD 44 20 Oct 1, 1999 5,67,87,389 Bank Of America, AVP Global Head – Financial Services & Insurance and Strategic Global Sourcing Balakrishna D. R. AVP and Consulting and BE 40 18 Feb 7, 1994 67,87,064 HCL – HP, Customer Systems Integration Practice Engineer – Trainee Head, Energy, Utilities, Communications and Services – SAP, ECSSAP Balakrishnan V. Director and Chief B.Sc, ACA, ACS, 47 25 Sep 2, 1991 2,96,16,476 Amco Batteries Limited, Financial Officer AICWA Senior Accounts Executive Bhuvaneswari VP and Delivery Head – B.Sc, MCA 47 24 Aug 28, 2000 74,39,750 Citibank, AVP Sundaram ADM, Financial Services and Insurance, FSIADM Binod H. R. SVP and Global Head – BE 49 26 Aug 2, 1993 83,61,969 MICO, Senior Engineer, Corporate Relations and Technical Sales Commercial, CORP Chandra Shekar Kakal SVP and Member – Diploma, BE, 51 28 Mar 1, 1999 2,35,49,676 Ramco Systems, Product Executive Council and PGD, MBA Manager Global Head – Business IT Services, CORPADM Chandraketu Jha VP and Head – B.Com, CA 48 25 Jun 26, 2000 82,48,082 Global Business Commercial, Purchase Dimensions, Head of Accounts and Finance Charles Henry Hawkes VP and Head – Facilities B.Sc, PGCBM 52 27 Nov 15, 1996 69,99,980 Trans Oceanic Travel, Manager Deepak N. -
Ajanta Pharma Limited
AJANTA PHARMA LIMITED CIN : L24230MH1979PLC022059 Registered & Corporate Office: ‘Ajanta House’, 98 Govt Industrial Area, Charkop, Kandivli (West), Mumbai - 400 067, Maharashtra, India Tel.: +91 22 6606 1000, Fax: +91 22 6606 1200 | E-mail: [email protected] | Website: www.ajantapharma.com POST BUYBACK PUBLIC ANNOUNCEMENT FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF EQUITY SHARES OF AJANTA PHARMA LIMITED This public announcement (the “Post Buyback Public Announcement”) is being made pursuant to the provisions of Regulation 24(vi) of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, for the time being in force including any statutory modifications and amendments from time to time (the “Buyback Regulations”). This Post Buyback Public Announcement should be read in conjunction with the Public Announcement dated November 4, 2020 which was published on November 5, 2020 (the “Public Announcement”) and the letter of offer dated November 25, 2020 (the “Letter of Offer”) issued in connection with the Buyback. The terms used but not defined in this Post Buyback Public Announcement shall have the same meanings as assigned in the Public Announcement and the Letter of Offer. 1. THE BUYBACK 1.1 Ajanta Pharma Limited (the “Company”) had announced the Buyback of not exceeding 7,35,000 (Seven Lakh Thirty Five Thousand) fully paid-up equity shares of face value of ₹2 each (“Equity Shares”) from all the existing shareholders / beneficial owners of Equity Shares as on the record date (i.e. Friday, November 13, 2020), on a proportionate basis, through the “Tender Offer” process at a price of ₹1,850/- (Rupees One Thousand Eight Hundred and Fifty Only) per Equity Share payable in cash for an aggregate consideration not exceeding ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) excluding the Transaction Costs (“Buyback Offer Size”). -
Inner 25 India Pharma & Healthcare Fund
Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata India Pharma & Healthcare Fund o i L g (An open ended equity scheme investing in Pharma and Healthcare Services Sector) h Riskometer Investors understand that their principal As on 30th June 2021 PORTFOLIO will be at Very High Risk INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India. Equity & Equity Related Total 55184.24 97.88 Glenmark Pharmaceuticals Ltd. 167000 1089.76 1.93 INVESTMENT OBJECTIVE Healthcare Services Sanofi India Ltd. 13000 997.39 1.77 The investment objective of the scheme is to seek long Apollo Hospitals Enterprise Ltd. 70500 2551.99 4.53 Gland Pharma Ltd. 19662 673.29 1.19 term capital appreciation by investing atleast 80% of its Fortis Healthcare Ltd. 795000 1935.03 3.43 Laurus Labs Ltd. 90000 619.79 1.10 net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in Syngene International Ltd. 265000 1545.75 2.74 India.However, there is no assurance or guarantee that the investment objective of the Scheme will be Narayana Hrudayalaya Ltd. 301420 1483.74 2.63 Other Equities^ 1186.14 2.10 achieved.The Scheme does not assure or guarantee any Metropolis Healthcare Ltd.